Hsp90 chaperones PPARγ and regulates differentiation and survival of 3T3-L1 adipocytes
Adipose tissue dysregulation has a major role in various human diseases. The peroxisome proliferator-activated receptor- γ (PPAR γ ) is a key regulator of adipocyte differentiation and function, as well as a target of insulin-sensitizing drugs. The Hsp90 chaperone stabilizes a diverse set of signali...
Saved in:
Published in | Cell death and differentiation Vol. 20; no. 12; pp. 1654 - 1663 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
01.12.2013
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Adipose tissue dysregulation has a major role in various human diseases. The peroxisome proliferator-activated receptor-
γ
(PPAR
γ
) is a key regulator of adipocyte differentiation and function, as well as a target of insulin-sensitizing drugs. The Hsp90 chaperone stabilizes a diverse set of signaling ‘client’ proteins, thereby regulates various biological processes. Here we report a novel role for Hsp90 in controlling PPAR
γ
stability and cellular differentiation. Specifically, we show that the Hsp90 inhibitors geldanamycin and novobiocin efficiently impede the differentiation of murine 3T3-L1 preadipocytes. Geldanamycin at higher concentrations also inhibits the survival of both developing and mature adipocytes, respectively. Further, Hsp90 inhibition disrupts an Hsp90-PPAR
γ
complex, leads to the destabilization and proteasomal degradation of PPAR
γ
, and inhibits the expression of PPAR
γ
target genes, identifying PPAR
γ
as an Hsp90 client. A similar destabilization of PPAR
γ
and a halt of adipogenesis also occur in response to protein denaturing stresses caused by a single transient heat-shock or proteasome inhibition. Recovery from stress restores PPAR
γ
stability and adipocyte differentiation. Thus, our findings reveal Hsp90 as a critical stress-responsive regulator of adipocyte biology and offer a potential therapeutic target in obesity and the metabolic syndrome. |
---|---|
ISSN: | 1350-9047 1476-5403 |
DOI: | 10.1038/cdd.2013.129 |